References
- Autism: present challenges, future needs — why the increased rates? Committee on Government Reform, House of Representatives, 106th Congress, April 6th (2000).
- Madsen KM, Hvid A, Vestergaard M et at A population-based study of measles, mumps and rubella vaccination and autism. N. Engl. Med. 347, 1477–1482 (2002).
- Taylor B, Miller E, Farrington P et al. Autism and measles, mumps and rubella vaccine: no epidemiologic evidence for a causal association. Lancet 353, 2026–2029 (1999).
- Farrington CP, Miller E, Taylor B. MMR and autism: further evidence against a causal association. Vaccine 19, 3632–3635 (2001).
- Dales L, Hammer SJ, Smith NJ. Time trends in autism and in MMR immunization coverage in California. JA M4 285, 1183–1185 (2001).
- Kaye JA, Melero-Montes M, Jick H. Mumps, measles and rubella vaccine and the incidence of autism recorded by general practitioners: a time trend analysis. Br. Med.j 322, 460–463 (2001).
- Taylor B, Miller E, Lingam R et al. Measles, mumps and rubella vaccination and bowel problems or developmental regression in children with autism: population study. Br. Med.j 324, 393–396 (2002).
- Fombonne E, Chalcrabarti S. No evidence for a new variant of measles—mumps—rubella-induced autism. Pediatrics 108, e58 (2001).
- Mäkeld A, Nuorti P, Peltola H. Neurologic disorders after measles—mumps—rubella vaccination. Pediatrics 110, 957–963 (2002).
- Nisbett RE, Borgida E, Crandall R, Reed H. Popular induction: information is not necessarily informative. In: Judgement under uncertainty' heuristics and biases. Kahnemann D, Siovic P, Tversky A (Eds). Cambridge University Press, Cambridge, UK (1982).
- Steere AC, Sikand VK, Meurice F etal. Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. N Engl. Med. 339, 209–215 (1998).
- Sigg LH, Zahradnik JM, Lavin P et al A vaccine consisting of recombinant Borrelia burgdorferi outer surface protein A to prevent Lyme disease. N Engl J. Med 339, 216–222 (1998).
- Steere AC, Gross D, Meyer AL, Huber BT Autoimmune mechanisms in antibiotic treatment-resistant Lyme arthritis. J. Autoimmunity 16, 263–268 (2001).
- Kulenkampff M, Schwartzman JS, Wilson J. Neurological complications of pertussis inoculation. Arch. Dis. Child. 49, 46–49 (1974).
- Gangarosa EJ, Galazka AM, Wolfe CR etal. Impact of antivaccine movements on pertussis control: the untold story. Lancet 351, 356–361 (1998).
- Cody CL, Baraff LJ, Cherry JD et al. Nature and rates of adverse reactions associated with DTP and DT immunizations in infants and children. Pediatrics 68, 650–660 (1981).
- Pollock TM, Morris J. A 7-year survey of disorders attributed to vaccination in Northwest Thames Region. Lancet 1, 753–757 (1983).
- Walker AM, Jick H, Perera DR etal. Neurologic events following diphtheria—tetanus—pertussis immunization. Pediatrics 81, 345–349 (1988).
- Griffin MR, Ray WA, Schaffner W etal. Risk of seizures and encephalopathy after immunization with diphtheria—tetanus—pertussis vaccine. JA/VIA 263, 1641–1645 (1990).
- Shields WD, Nielsen C, Buch D et al. Relationship of pertussis immunization to the onset of neurologic disorders.' Pediatr 113, 801–805 (1988).
- Gale JL, Thapa PB, Wassilak SGF etal. Risk of serious acute neurological illness after immunization with diphtheria—tetanus—pertussis vaccine: a population-based case-control study. JA/VIA 271, 37–41 (1994).
- Golden GS. Pertussis vaccine and injury to the brain. J. Pediatr 116, 854–861 (1990).